News >

Targeted Therapies Transform Outlook of FLT3- and IDH-Mutant AML

Caroline Seymour
Published: Wednesday, May 08, 2019

Lyndsey Runaas, MD

Lyndsey Runaas, MD

FLT3 and IDH1/2 mutations carry prognostic significance, and now therapeutic implications for patients with both newly diagnosed and relapsed/refractory acute myeloid leukemia (AML), explained Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication